Picture of Replimune logo

REPL Replimune Cashflow Statement

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousMid CapNeutral

Annual cashflow statement for Replimune, fiscal year end - March 31st, USD millions except per share, conversion factor applied.

2019
March 31st
2020
March 31st
2021
March 31st
2022
March 31st
2023
March 31st
Period Length:12 M12 M12 M12 M12 M
Source:10-K10-K10-K10-K10-K
Standards:
USG
USG
USG
USG
USG
Status:FinalFinalFinalFinalFinal
Net Income/Starting Line-30.8-52.6-80.9-118-174
Depreciation
Non-Cash Items6.566.9514.326.528.7
Unusual Items
Other Non-Cash Items
Changes in Working Capital-1.25-15.43.517.2415.1
Change in Accounts Receivable
Change in Prepaid Expenses
Change in Other Assets
Change in Accounts Payable
Change in Accrued Expenses
Change in Other Liabilities
Cash from Operating Activities-25.4-60.6-61.4-82.2-128
Capital Expenditures-2.6-6.54-2.39-2.34-2.27
Purchase of Fixed Assets
Other Investing Cash Flow Items-63.31.31-1860.53-140
Sale/Maturity of Investment
Purchase of Investments
Cash from Investing Activities-65.9-5.23-189-1.81-143
Financing Cash Flow Items-2.16-0.355-0.8950
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities1011003726.6311
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash9.2334.2123-76.640.6